Skip to main content

Table 1 Characteristics of participants by study area

From: Resisting and tolerating P. falciparum in pregnancy under different malaria transmission intensities

 

HIV-uninfecteda

HIV-infectedb

All

Benin

Gabon

Mozambique

All

Kenya

Mozambique

n = 946

n = 349

n = 257

n = 340

n = 768

n = 351

n = 417

Age (years), mean (SD)

 

24.3 (6.3)

25.4 (5.2)

24.4 (6.7)

23.1 (6.8)

26.7 (5.7)

26.9 (5.4)

26.5 (5.9)

Parity, n (%)

 Primigravidae

265 (28)

69 (20)

66 (26)

130 (38)

81 (11)

30 (9)

51 (12)

 Multigravidae

681 (72)

280 (80)

191 (74)

210 (62)

687 (89)

321 (91)

366 (88)

Gestational age at baseline (weeks), mean (SD)

 

21.0 (4.9)

22.0 (4.1)

19.5 (5.4)

21.3 (5.2)

20.3 (5.5)

19.9 (5.9)

20.6 (5.2)

MUAC at baseline (cm), mean (SD)

 

25.9 (3.0)

25.3 (2.3)

25.7 (3.6)

26.8 (3.0)

26.8 (2.7)

27.0 (2.7)

26.7 (2.7)

RPR at baseline, n (%)

 Positive

9 (1)

2 (1)

1 (0)

6 (2)

39 (5)

12 (3)

27 (7)

 Negative

928 (99)

347 (99)

247 (100)

334 (98)

726 (95)

338 (97)

388 (93)

Literate, n (%)

 No

371 (39)

280 (80)

34 (13)

57 (17)

142 (18)

16 (5)

126 (30)

 Yes

575 (61)

69 (20)

223 (87)

283 (83)

626 (82)

335 (95)

291 (70)

HIV viral load (copies/mL) at baseline, n (%)c

  < 399

    

181 (24)

125 (36)

56 (13)

 400/999

    

183 (24)

76 (22)

107 (26)

 1000/9999

    

243 (32)

97 (28

146 (35)

 10,000/max

    

123 (16)

49 (14)

74 (18)

 UNK

    

38 (5)

4 (1)

34 (8)

CD4 (cells/μL) at baseline, n (%)d

  < 350

    

279 (36)

137 (39)

142 (34)

 350/max

    

460 (60)

212 (60)

248 (59)

 UNK

    

29 (4)

2 (1)

27 (6)

Maternal haemoglobin at baseline (g/dL), mean (SD)

 

10.4 (1.5)

10.3 (1.2)

10.3 (1.4)

10.7 (1.8)

10.1 (1.7)

10.2 (1.9)

10.0 (1.6)

IPTp, n (%)

 Antimalarial 1e

629 (66)

230 (66)

172 (67)

227 (67)

390 (51)

174 (50)

216 (52)

 Antimalarial 2e

317 (34)

119 (34)

85 (33)

113 (33)

378 (49)

177 (50)

201 (48))

Gestational age at delivery (weeks),f mean (SD)

 

39.6 (1.7)

39.2 (1.2)

41.1 (1.8)

38.9 (1.2)

38.8 (1.2)

ND

38.8 (1.2)

Preterm birth,g n (%)

 No

867 (95)

328 (95)

238 (95)

301 (95)

374 (96)

ND

374 (96)

 Yes

44 (5)

16 (5)

13 (5)

15 (5)

17 (4)

ND

17 (4)

  1. aThe IPTp trial evaluated the efficacy and safety of two doses of Intermittent Preventive Treatment in pregnancy (IPTp) with mefloquine compared to IPTp with sulphadoxine-pyrimethamine
  2. bEvaluated three doses of IPTp with MQ compared to placebo in HIV-infected women on cotrimoxazole prophylaxis
  3. c38 missing values
  4. d29 missing values
  5. eAntimalarial: 1 = Mefloquine and 2 = Sulphadoxine-Pyrimethamine for HIV-uninfected; 1 = Placebo and 2 = Mefloquine for HIV-infected
  6. fGestational age was estimated by newborn physical examination using the Ballard score
  7. gPreterm birth if gestational age was < 37 weeks
  8. IPTp intermittent preventive treatment, MUAC mid-upper arm circumference, RPR rapid plasma reagin, UNK unknown